Haemonetics (HAE) reported fiscal Q3 adjusted earnings Thursday of $1.19 per diluted share, up from $1.04 a year earlier.
Three analysts polled by FactSet expected $1.11.
Net revenue for the quarter ended Dec. 28 was $348.5 million, up from $336.3 million.
Analysts polled by FactSet expected $353 million.
The company narrowed its fiscal year 2025 adjusted EPS to $4.50 to $4.70 from $4.45 to $4.75. Three analysts surveyed by FactSet are looking for $4.35.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。